Skip to main content
SpringerLink
Log in
Book cover

Leading Pharmaceutical Innovation pp 41–61Cite as

The Science and Technology Challenge: How to Find New Drugs

  • Chapter
  • First Online:

  • 1967 Accesses

Abstract

Already a high-tech industry by virtue of its science underpinnings, pharma innovation is undergoing a major shift in the wake of the adoption of several new discovery and development technologies. The rise of the biotech industry is the most obvious one, but new approaches in target discovery, high-throughput screening, combinatorial chemistry, hit and lead generation, bioinformatics, big data, proteomics and pharmacogenetics are also radically changing how pharma R&D is being done at the lab level.

“The stakes are too high, the medical need too great,and the science too compelling for all of us to dobusiness as usual.”

Mikael Dolston,

President of Woldwide R&D, Pfizer

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   49.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Notes

  1. 1.

    With thanks to Dr. Lars Greifenberg, Director R&D IT, AbbVie Deutschland.

Bibliography

  • Agrafiotis, D. K., Alex, S., Dai, H., Derkinderen, A., Farnum, M., Gates, P., et al. (2007). Advanced biological and chemical discovery (ABCD): Centralizing discovery knowledge in an inherently decentralized world. Journal of Chemical Informatics and Modeling, 47, 1999–2014.

    Article  Google Scholar 

  • Agrafiotis, D. K., Lobanov, V. S., & Salemme, F. R. (2002). Combinatorial informatics in the post-genomics era. Nature Reviews Drug Discovery, 1, 337–346.

    Article  Google Scholar 

  • Baumann, G. (2003). The challenge of innovation in the drug discovery process. Presentation at CTO-Roundtable ‘Management of Pharmaceutical R&D in Turbulent Times – Perspectives and Trends’. Zurich 2003.

    Google Scholar 

  • Beckman, R. A., Clark, J., & Chen, C. (2011). Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nature Reviews Drug Discovery, 10, 735–748.

    Article  Google Scholar 

  • Bleicher, K. H., Böhm, H. J., Müller, K., & Alanine, A. I. (2003). A guide to drug discovery: Hit and lead generation: Beyond high-throughput screening. Nature Reviews Drug Discovery, 2, 369–378.

    Article  Google Scholar 

  • Booz Allen & Hamilton. (1997). In vivo, making combinatory chemistry pay. New York: Booz Allen & Hamilton Report.

    Google Scholar 

  • Butcher, E. C. (2005). Can cell systems biology rescue drug discovery? Nature Reviews Drug Discovery, 4, 461–467.

    Article  Google Scholar 

  • Davis, S., & Botkin, J. (1994). The coming of knowledge-based business. Harvard Business Review, 5, 165–170.

    Google Scholar 

  • Eder, J., Sedrani, R., & Wiesmann, C. (2014). The discovery of first-in-class drugs: Origins and evolution. Nature Reviews Drug Discovery, 13, 577–587.

    Article  Google Scholar 

  • Evaluate. (2015). World preview 2015, outlook to 2020. http://info.evaluategroup.com/rs/607-YGS-364/images/wp15.pdf. Accessed 15 Feb 2016.

  • FDA. (2014). Guidance for industry and FDA staff qualification process for drug development tools. Silver Spring: FDA.

    Google Scholar 

  • Gassmann, O., & Keupp, M. M. (2007). The competitive advantage of early and rapidly internationalising SMEs in the biotechnology industry: A knowledge based view. Journal of World Business, 42, 350–366.

    Article  Google Scholar 

  • Hajduk, P. J., & Greer, J. (2007). A decade of fragment-based drug design: Strategic advances and lessons learned. Nature Reviews Drug Discovery, 6, 211–219.

    Article  Google Scholar 

  • HHS & FDA. (2005). Drug-diagnostic co-development concept paper. Department of Health and Human Services.

    Google Scholar 

  • Hurko, O., & Jones, G. K. (2011). Valuation of biomarkers. Nature Reviews Drug Discovery, 10, 253–254.

    Article  Google Scholar 

  • Kinch, M. S. (2015). An overview of FDA-approved biologics medicines. Drug Discovery Today, 20, 393–398.

    Article  Google Scholar 

  • Kitano, H. (2002). Computational systems biology. Nature, 420, 206–210.

    Article  Google Scholar 

  • Kogej, T., Blomberg, N., Greasley, P. J., Mundt, S., Vainio, M. J., Schamberger, J., et al. (2013). Big pharma screening collections: More of the same or unique libraries? The AstraZeneca–Bayer pharma AG case. Drug Discovery Today, 18, 1014–1024.

    Article  Google Scholar 

  • Kramer, R., & Coher, D. (2004). Functional genomics to new drug targets. Nature Reviews Drug Discovery, 3, 965–972.

    Article  Google Scholar 

  • Lin, B.-W. (2001). Strategic alliances and innovation networks in the biopharmaceutical industry. Hsinchu: Institute of Technology Management, National Tsinghua University.

    Google Scholar 

  • Macarron, R. (2006). Critical review of the role of HTS in drug discovery. Drug Discovery Today, 11, 277–279.

    Article  Google Scholar 

  • Macarron, R., Banks, M. N., Bojanic, D., Burns, D. J., Cirovic, D. A., Garyantes, T., et al. (2011). Impact of high-throughput screening in biomedical research. Nature Reviews Drug Discovery, 10, 188–195.

    Article  Google Scholar 

  • Manji, H. K., Inel, T. R., & Narayan, V. A. (2014). Harnessing the informatics revolution for neuroscience drug R&D. Nature Reviews Drug Discovery, 13, 561–562.

    Article  Google Scholar 

  • Mohamed, S., & Syed, B. A. (2013). Commercial prospects for genomic sequencing technologies. Nature Reviews Drug Discovery, 12, 341–342.

    Article  Google Scholar 

  • Nicholson, J. K., Connelly, J., Lindon, J. C., & Holmes, E. (2002). Metabonomics: A platform for studying drug toxicity and gene function. Nature Reviews Drug Discovery, 1, 153–161.

    Article  Google Scholar 

  • Nightingale, P. (2000). Economies of scale in experimentation: Knowledge and technology in pharmaceutical R&D. Industrial and Corporate Change, 9(2), 315–359.

    Article  Google Scholar 

  • Paolini, G. V., Shapland, R. H. B., Hoorn van, W. P., Mason, J. S., & Hopins, A. L. (2006). Global mapping of pharmacological space. Nature Biotechnology, 24, 805–815.

    Article  Google Scholar 

  • Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013). Validating therapeutic targets through human genetics. Nature Reviews Drug Discovery, 12, 581–594.

    Article  Google Scholar 

  • Rask-Andersen, M., Sällman Almén, M., & Schiöth, H. B. (2011). Trends in the exploitation of novel drug targets. Nature Reviews Drug Discovery, 10, 579–590.

    Article  Google Scholar 

  • Recombinant Capital. (2005). Analyst’s notebook. Trends. http://www.recap.com/consulting.nsf/ANB_tab_trends?openform. Accessed 11 Feb 2005.

  • Reuters. (2002). Pharmaceutical innovation – an analysis of leading companies and strategies. Reuters Business Insight, Healthcare.

    Google Scholar 

  • Robbins-Roth, C. (2001). Zukunftsbranche Biotechnologie. Gabler.

    Book  Google Scholar 

  • Searls, D. B. (2003). Pharmacophylogenomics: Genes, evolution and drug targets. Nature Reviews Drug Discovery, 2, 613–623.

    Article  Google Scholar 

  • Swinney, D. C., & Anthony, J. (2011). How were new medicines discovered? Nature Reviews Drug Discovery, 10, 507–519.

    Article  Google Scholar 

  • Ulrich, R., & Friend, S. H. (2002). Toxicogenomics and drug discovery: Will new technologies help us produce better drugs? Nature Reviews Drug Discovery, 1, 84–88.

    Article  Google Scholar 

  • van der Greef, J., & McBurney, N. (2005). Rescuing drug discovery: In vivo systems pathology and systems pharmacology. Nature Reviews Drug Discovery, 4, 961–967.

    Article  Google Scholar 

  • Wenk, M. R. (2005). The emerging field of lipidomics. Nature Reviews Drug Discovery, 4, 594–610.

    Article  Google Scholar 

  • Whittaker, E., & Bower, D. J. (1994). A shift to external alliances for product development in the pharmaceutical industry. R&D Management, 24(3), 249–260.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Technology Management, University of St. Gallen, St. Gallen, Switzerland

    Oliver Gassmann

  2. Faculty of Applied Chemistry, Reutlingen University, Reutlingen, Germany

    Alexander Schuhmacher

  3. Department of Strategic Management, Kaunas University of Technology, Kaunas, Lithuania

    Max von Zedtwitz

  4. Novi, MI, USA

    Gerrit Reepmeyer

Authors
  1. Oliver Gassmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander Schuhmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Max von Zedtwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gerrit Reepmeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Gassmann, O., Schuhmacher, A., von Zedtwitz, M., Reepmeyer, G. (2018). The Science and Technology Challenge: How to Find New Drugs. In: Leading Pharmaceutical Innovation. Springer, Cham. https://doi.org/10.1007/978-3-319-66833-8_3

Download citation

Publish with us

Policies and ethics

Search

Navigation